Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.

Our results support efficacy and tolerability of teriflunomide for treatment-naïve RRMS patients in real-world practice. Female patients, patients with less relapses and less disability before treatment are most likely to benefit from teriflunomide treatment.